Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation

被引:18
|
作者
Xu, Xi [1 ,2 ]
Ren, Jie [1 ,2 ]
Ma, Yinghe [1 ,2 ]
Liu, Hongting [1 ]
Rong, Quanjin [1 ]
Feng, Yifan [1 ]
Wang, Yameng [1 ]
Cheng, Yu [1 ]
Ge, Ruijia [3 ]
Li, Zhiyu [1 ,2 ]
Bian, Jinlei [1 ,2 ]
机构
[1] China Pharmaceut Univ, State Key Lab Nat Med, Jiangsu Key Lab Drug Design & Optimizat, Nanjing 210009, Jiangsu, Peoples R China
[2] China Pharmaceut Univ, Sch Pharm, Dept Med Chem, Nanjing, Jiangsu, Peoples R China
[3] Madeira Sch, Mclean, VA USA
基金
美国国家科学基金会; 中国国家自然科学基金;
关键词
Indoleamine 2,3-dioxygenase 1; inhibitor; virtual screen; cyanopyridine scaffold; hit optimisation; INDOLEAMINE 2,3-DIOXYGENASE; TRYPTOPHAN DEGRADATION; CRYSTAL-STRUCTURES; POTENT INHIBITORS; MOLECULAR DOCKING; DETAILED ANALYSIS; DENDRITIC CELLS; DERIVATIVES; DESIGN; EXPRESSION;
D O I
10.1080/14756366.2018.1480614
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
With the aim of discovering novel IDO1 inhibitors, a combined similarity search and molecular docking approach was employed to the discovery of 32 hit compounds. Testing the screened hit compounds has led to several novel submicromolar inhibitors. Especially for compounds LVS-019 with cyanopyridine scaffold, showed good IDO1 inhibitory activity. To discover more compounds with similar structures to LVS-019, a shape-based model was then generated on the basis of it and the second-round virtual screening was carried out leading to 23 derivatives. Molecular docking studies suggested a possible binding mode of LVS-019, which provides a good starting point for the development of cyanopyridine scaffold compounds as potent IDO1 inhibitor. To improve potency of these hits, we further designed and synthesised another 14 derivatives of LVS-019. Among these compounds, LBJ-10 showed improved potency compared to the hits and displayed comparable potency to the control GDC-0919 analogue. LBJ-10 can serve as ideal leads for further modifications as IDO1 inhibitors for cancer treatment.
引用
收藏
页码:250 / 263
页数:14
相关论文
共 50 条
  • [21] Synthesis and Molecular Modeling Studies of N′-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
    Lee, Dong-Ho
    Lee, Joo-Youn
    Jeong, Jieun
    Kim, Miok
    Lee, Kyung Won
    Jang, Eunseo
    Ahn, Sunjoo
    Lee, Chang Hoon
    Hwang, Jong Yeon
    MOLECULES, 2017, 22 (11):
  • [22] Discovery and characterization of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening
    Guo, Wei
    Yao, Sheng
    Sun, Pu
    Yang, Tian-biao
    Tang, Chun-ping
    Zheng, Ming-yue
    Ye, Yang
    Meng, Ling-hua
    ACTA PHARMACOLOGICA SINICA, 2020, 41 (03) : 423 - 431
  • [23] Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor
    Moyer, Benjamin J.
    Rojas, Itzel Y.
    Murray, Iain A.
    Lee, Seokwon
    Hazlett, Haley F.
    Perdew, Gary H.
    Tomlinson, Craig R.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2017, 323 : 74 - 80
  • [24] Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors
    Dolusic, Eduard
    Larrieu, Pierre
    Blanc, Sebastien
    Sapunaric, Frederic
    Pouyez, Jenny
    Moineaux, Laurence
    Colette, Delphine
    Stroobant, Vincent
    Pilotte, Luc
    Colau, Didier
    Ferain, Thierry
    Fraser, Graeme
    Galleni, Moreno
    Frere, Jean-Marie
    Masereel, Bernard
    Van den Eynde, Benoit
    Wouters, Johan
    Frederick, Raphael
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2011, 46 (07) : 3058 - 3065
  • [25] Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme
    Hamilton, Matthew M.
    Mseeh, Faika
    McAfoos, Timothy J.
    Leonard, Paul G.
    Reyna, Naphtali J.
    Harris, Angela L.
    Xu, Alan
    Han, Michelle
    Soth, Michael J.
    Czako, Barbara
    Theroff, Jay P.
    Mandal, Pijus K.
    Burke, Jason P.
    Virgin-Downey, Brett
    Petrocchi, Alessia
    Pfaffinger, Dana
    Rogers, Norma E.
    Parker, Connor A.
    Yu, Simon S.
    Jiang, Yongying
    Krapp, Stephan
    Lammens, Alfred
    Trevitt, Graham
    Tremblay, Martin R.
    Mikule, Keith
    Wilcoxen, Keith
    Cross, Jason B.
    Jones, Philip
    Marszalek, Joseph R.
    Lewis, Richard T.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (15) : 11302 - 11329
  • [26] Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1)
    White, Catherine
    McGowan, Meredeth A.
    Zhou, Hua
    Sciammetta, Nunzio
    Fradera, Xavier
    Lim, Jongwon
    Joshi, Elizabeth M.
    Andrews, Christine
    Nickbarg, Elliott B.
    Cowley, Phillip
    Trewick, Sarah
    Augustin, Martin
    von Koeenig, Konstanze
    Lesburg, Charles A.
    Otte, Karin
    Knemeyer, Ian
    Woo, Hyun
    Yu, Wensheng
    Cheng, Mangeng
    Spacciapoli, Peter
    Geda, Prasanthi
    Song, Xuelei
    Smotrov, Nadya
    Curran, Patrick
    Heo, Mee Ra
    Abeywickrema, Pravien
    Miller, J. Richard
    Bennett, David Jonathan
    Han, Yongxin
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (04): : 550 - 557
  • [27] Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
    Bonanno, Giuseppina
    Mariotti, Andrea
    Procoli, Annabella
    Folgiero, Valentina
    Natale, Daniela
    De Rosa, Luca
    Majolino, Ignazio
    Novarese, Linda
    Rocci, Alberto
    Gambella, Manuela
    Ciciarello, Marilena
    Scambia, Giovanni
    Palumbo, Antonio
    Locatelli, Franco
    De Cristofaro, Raimondo
    Rutella, Sergio
    JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
  • [28] Nitrobenzofurazan derivatives of N′-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1
    Paul, Saurav
    Roy, Ashalata
    Deka, Suman Jyoti
    Panda, Subhankar
    Trivedi, Vishal
    Manna, Debasis
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 121 : 364 - 375
  • [29] Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy
    Tang, Kai
    Wang, Bo
    Yu, Bin
    Liu, Hong-Min
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 227
  • [30] Fused Heterocyclic Compounds as Potent Indoleamine-2,3-dioxygenase 1 Inhibitors
    Panda, Subhankar
    Roy, Ashalata
    Deka, Suman Jyoti
    Trivedi, Vishal
    Manna, Debasis
    ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (12): : 1167 - 1172